ABT

SEC source: 0001415889-22-001738 · form4-02232022_050221.xml · nonDerivative · entry 1

Ginascol John F · CIK 0001778075 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 130,921

F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

SEC source: 0001415889-22-001740 · form4-02232022_050218.xml · derivative · entry 2

MANNING JOSEPH J · CIK 0001695686 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,342

Underlying: Common Shares · 72,342 shares

Expires 2032-02-17

F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 24,114 on February 18, 2023, 24,114 on February 18, 2024, and 24,114 on February 18, 2025.

SEC source: 0001415889-22-001740 · form4-02232022_050218.xml · nonDerivative · entry 1

MANNING JOSEPH J · CIK 0001695686 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,502

F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

F2 · balance_after: Since the date of the reporting person's last ownership report, he transferred 3,754 shares to his ex-spouse pursuant to a domestic relations order. The reporting person no longer reports as beneficially owned any securities owned by his ex-spouse.

SEC source: 0001415889-22-001739 · form4-02232022_050241.xml · derivative · entry 1

Karam Sammy · CIK 0001766718 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,708

Underlying: Common Shares · 59,708 shares

Expires 2032-02-17

F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 19,902 on February 18, 2023, 19,903 on February 18, 2024, and 19,903 on February 18, 2025.

SEC source: 0001415889-22-001741 · form4-02232022_050219.xml · derivative · entry 5

Mateus Fernando · CIK 0001895703 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,852

Underlying: Common Shares · 48,852 shares

Expires 2032-02-17

F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 16,284 on February 18, 2023, 16,284 on February 18, 2024, and 16,284 on February 18, 2025.

SEC source: 0001415889-22-001741 · form4-02232022_050219.xml · nonDerivative · entry 1

Mateus Fernando · CIK 0001895703 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,142

F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

SEC source: 0001415889-22-001742 · form4-02232022_050234.xml · derivative · entry 5

Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,696

Underlying: Common Shares · 73,696 shares

Expires 2032-02-17

F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 24,565 on February 18, 2023, 24,565 on February 18, 2024, and 24,566 on February 18, 2025.

SEC source: 0001415889-22-001742 · form4-02232022_050234.xml · nonDerivative · entry 1

Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,158

F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

SEC source: 0001415889-22-001743 · form4-02232022_050216.xml · derivative · entry 3

Morrone Louis H. · CIK 0001867666 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,280

Underlying: Common Shares · 54,280 shares

Expires 2032-02-17

F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 18,093 on February 18, 2023, 18,093 on February 18, 2024, and 18,094 on February 18, 2025.

SEC source: 0001415889-22-001743 · form4-02232022_050216.xml · nonDerivative · entry 1

Morrone Louis H. · CIK 0001867666 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,876

F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

SEC source: 0001415889-22-001744 · form4-02232022_050251.xml · derivative · entry 2

Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,474

Underlying: Common Shares · 111,474 shares

Expires 2032-02-17

F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 37,158 on February 18, 2023, 37,158 on February 18, 2024, and 37,158 on February 18, 2025.

SEC source: 0001415889-22-001744 · form4-02232022_050251.xml · nonDerivative · entry 1

Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 124,349

F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

SEC source: 0001415889-22-001745 · form4-02232022_050219.xml · derivative · entry 3

PEDERSON MICHAEL J · CIK 0001712233 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,710

Underlying: Common Shares · 40,710 shares

Expires 2032-02-17

F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 13,570 on February 18, 2023, 13,570 on February 18, 2024, and 13,570 on February 18, 2025.

SEC source: 0001415889-22-001745 · form4-02232022_050219.xml · nonDerivative · entry 1

PEDERSON MICHAEL J · CIK 0001712233 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,306

F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

SEC source: 0001415889-22-001747 · form4-02232022_050203.xml · derivative · entry 2

Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,418

Underlying: Common Shares · 88,418 shares

Expires 2032-02-17

F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 29,472 on February 18, 2023, 29,473 on February 18, 2024, and 29,473 on February 18, 2025.

SEC source: 0001415889-22-001747 · form4-02232022_050203.xml · nonDerivative · entry 1

Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,754

F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

SEC source: 0001415889-22-001746 · form4-02232022_050236.xml · derivative · entry 7

Tyler Julie L. · CIK 0001867573 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,852

Underlying: Common Shares · 48,852 shares

Expires 2032-02-17

F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 16,284 on February 18, 2023, 16,284 on February 18, 2024 and 16,284 on February 18, 2025.

SEC source: 0001415889-22-001746 · form4-02232022_050236.xml · nonDerivative · entry 1

Tyler Julie L. · CIK 0001867573 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,254

F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

SEC source: 0001415889-22-001748 · form4-02232022_050235.xml · derivative · entry 3

Watkin Jared · CIK 0001645118 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,850

Underlying: Common Shares · 67,850 shares

Expires 2032-02-17

F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 22,616 on February 18, 2023, 22,617 on February 18, 2024, and 22,617 on February 18, 2025.

SEC source: 0001415889-22-001748 · form4-02232022_050235.xml · nonDerivative · entry 1

Watkin Jared · CIK 0001645118 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,342

F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

SEC source: 0001415889-22-001749 · form4-02232022_050209.xml · derivative · entry 1

Wellisch Alejandro D · CIK 0001717526 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,280

Underlying: Common Shares · 54,280 shares

Expires 2032-02-17

F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 18,093 on February 18, 2023, 18,093 on February 18, 2024, and 18,094 on February 18, 2025.

SEC source: 0001415889-22-001750 · form4-02232022_050209.xml · derivative · entry 3

WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,852

Underlying: Common Shares · 48,852 shares

Expires 2032-02-17

F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 16,284 on February 18, 2023, 16,284 on February 18, 2024, and 16,284 on February 18, 2025.

SEC source: 0001415889-22-001750 · form4-02232022_050209.xml · nonDerivative · entry 1

WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,225

F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

SEC source: 0001415889-22-000228 · form4-01042022_020147.xml · derivative · entry 1

Alpern Robert J · CIK 0001448074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,591

Underlying: Common Shares · 55 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-22-000232 · form4-01042022_020159.xml · derivative · entry 1

Gonzalez Patricia Paola · CIK 0001879701 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 323

Underlying: Common Shares · 234 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-22-000238 · form4-01042022_020103.xml · derivative · entry 1

Roman Michael F · CIK 0001577544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 705

Underlying: Common Shares · 234 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-22-000250 · form4-01042022_020145.xml · derivative · entry 1

Stratton John G · CIK 0001385262 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,216

Underlying: Common Shares · 234 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-21-006265 · form4-12282021_021257.xml · derivative · entry 8

Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,226

Underlying: Common Shares · 3,000 shares

Expires 2025-02-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-21-006265 · form4-12282021_021257.xml · nonDerivative · entry 5

Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,782

SEC source: 0001415889-21-006265 · form4-12282021_021257.xml · nonDerivative · entry 4

Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,782

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-21-006263 · form4-12282021_021241.xml · derivative · entry 5

Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,591

Underlying: Common Shares · 31,229 shares

Expires 2027-02-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-21-006263 · form4-12282021_021241.xml · derivative · entry 4

Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,771

Underlying: Common Shares · 23,771 shares

Expires 2026-02-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-21-006263 · form4-12282021_021241.xml · nonDerivative · entry 3

Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,430

SEC source: 0001415889-21-006263 · form4-12282021_021241.xml · nonDerivative · entry 2

Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 158,931

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-21-006263 · form4-12282021_021241.xml · nonDerivative · entry 1

Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 127,702

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-21-006264 · form4-12282021_021229.xml · nonDerivative · entry 1

Karam Sammy · CIK 0001766718 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,226

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140 to $140.01, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001415889-21-006265 · form4-12282021_021257.xml · derivative · entry 7

Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Shares · 10,000 shares

Expires 2026-02-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-21-006265 · form4-12282021_021257.xml · derivative · entry 6

Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,226

Underlying: Common Shares · 3,000 shares

Expires 2025-02-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-21-006265 · form4-12282021_021257.xml · nonDerivative · entry 3

Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,782

SEC source: 0001415889-21-006265 · form4-12282021_021257.xml · nonDerivative · entry 2

Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,782

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-21-006265 · form4-12282021_021257.xml · nonDerivative · entry 1

Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,782

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-21-006162 · form4-12212021_021252.xml · derivative · entry 4

Morrone Louis H. · CIK 0001867666 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 9,988 shares

Expires 2027-07-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-21-006162 · form4-12212021_021252.xml · nonDerivative · entry 2

Morrone Louis H. · CIK 0001867666 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,229

SEC source: 0001415889-21-006162 · form4-12212021_021252.xml · nonDerivative · entry 1

Morrone Louis H. · CIK 0001867666 · SENIOR VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,217

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-21-006161 · form4-12212021_021203.xml · derivative · entry 3

Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,226

Underlying: Common Shares · 7,500 shares

Expires 2025-02-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-21-006161 · form4-12212021_021203.xml · nonDerivative · entry 2

Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,782

SEC source: 0001415889-21-006161 · form4-12212021_021203.xml · nonDerivative · entry 1

Wainer Andrea F · CIK 0001778070 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,282

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-21-005966 · form4-12152021_031259.xml · derivative · entry 3

CAPEK JOHN M · CIK 0001328034 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 149,600 shares

Expires 2023-02-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-21-005966 · form4-12152021_031259.xml · nonDerivative · entry 2

CAPEK JOHN M · CIK 0001328034 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 321,398

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.00 to $135.295 inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001415889-21-005966 · form4-12152021_031259.xml · nonDerivative · entry 1

CAPEK JOHN M · CIK 0001328034 · EXECUTIVE VICE PRESIDENT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 470,998

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.